XIAP and cancer: The authors stated that the study is a new insight on exploring NRF2 inhibition in combination with HER2-targeted trastuzumab as a potential clinical treatment regimen for treating HER2-positive cancers [109]; Very recently, Xie, et al. reported that in lung cancer cells, brusatol significantly suppressed the expression of NRF2 and HO-1 (a NRF2 downstream target), and abrogated tBHQ-induced NRF2 activation [110]; brusatol suppressed the expression level of Bcl-2 and Bcl-xl, accentuated Bax and Bak, increased cleaved caspases-3/8, and cleaved PARP but upregulated XIAP [110].